+
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Anti-vascular endothelial growth factor for the management of peripapillary choroidal neovascular membrane

Eye (2025)Cite this article

Subjects

Abstract

Objectives

To explore the evidence on the use of anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of peripapillary choroidal neovascular membrane (pCNVM).

Methods

Medline, Embase, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched between January 2000 and December 2024 for relevant articles that used anti-VEGF therapy to treat pCNVM of any origin. This review followed PRISMA guidelines and was prospectively registered (PROSPERO registration number CRD42024551949).

Results

Ten studies reporting on 269 eyes were included. The most common treatment strategy was pro re nata (PRN), used in 8 studies. One study used a fixed interval regimen, and another used a loading phase followed by PRN. Across all studies, the average number of anti-VEGF injections was 7 per eye over a mean follow-up duration of 34 months (range: 3–44 months). Eight studies reported improvements in best corrected visual acuity (BCVA) at final follow-up following treatment. The mean logarithm of the minimum angle of resolution (logMAR) change was 0.092, or approximately one line Snellen improvement. Two studies reported on macular thickness, and one reported on choroidal thickness after treatment, all of which noted decreased thickness at final follow-up. No significant complications were reported.

Conclusions

For patients with pCNVM of various aetiologies, anti-VEGF injections using any treatment strategy, including conservative management with a PRN approach, seem to be a safe and effective therapy associated with improved visual acuity.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

Data availability

All data generated or analysed during this study are included in this published article.

References

  1. Ruben S, Palmer H, Marsh RJ. The visual outcome of peripapillary choroidal neovascular membranes. Acta Ophthalmol (Copenh). 1994;72:118–21.

    Article  PubMed  Google Scholar 

  2. D’souza P, Ranjan R, Babu U, Kanakath AV, Saravanan VR. INFLAMMATORY CHOROIDAL NEOVASCULAR MEMBRANE: Long-Term Visual and Anatomical Outcomes After Intravitreal Anti–vascular Endothelial Growth Factor Therapy. RETINA. 2018;38:1307–15.

    Article  Google Scholar 

  3. Jutley G, Tah V, Lindfield D, Menon G. Treating peripapillary choroidal neovascular membranes: a review of the evidence. Eye (Lond). 2011;25:675–81.

    Article  PubMed  Google Scholar 

  4. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ Etiology of Choroidal Neovascularization in Young Patients. Ophthalmology. 1996;103:1241–4.

  5. Browning DJ, Fraser CM. Ocular conditions associated with peripapillary subretinal neovascularization, their relative frequencies, and associated outcomes. Ophthalmology. 2005;112:1054–61.

    Article  PubMed  Google Scholar 

  6. Lopez PF, Green WR. Peripapillary subretinal neovascularization. A review. Retina. 1992;12:147–71.

    Article  PubMed  Google Scholar 

  7. Wilde C, Poostchi A, Mehta RL, Hillman JG, MacNab HK, Messina M, et al. Prevalence of peripapillary choroidal neovascular membranes (PPCNV) in an elderly UK population—the Bridlington eye assessment project (BEAP): a cross-sectional study (2002–2006). Eye. 2018;33:451–8.

  8. Lin T, Dans K, Meshi A, Muftuoglu IK, Amador-Patarroyo MJ, Chen KC, et al. Age-Related Macular Degeneration-Associated Peripapillary Choroidal Neovascularization in the Era of Anti-Vascular Endothelial Growth Factor Therapy. Retina. 2019;39:1936–44.

    Article  PubMed  Google Scholar 

  9. Figueroa MS, Noval S, Contreras I. Treatment of peripapillary choroidal neovascular membranes with intravitreal bevacizumab. British J Ophthalmol. 2008;92:1244.

    Article  Google Scholar 

  10. Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. (2689-8381 (Electronic)).

  11. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

  12. Rabina G, Ayalon A, Mimouni M, Stanescu N, Moisseiev E, Nemet AY, et al. Optical Coherence Tomography Prognostic Factors in Age-Related Macular Degeneration Patients with Peripapillary Choroidal Neovascularization. Ophthalmologica. 2021;245:342–9.

    Article  PubMed  Google Scholar 

  13. Singh SR, Fung AT, Fraser-Bell S, Lupidi M, Mohan S, Gabrielle P-H, et al. One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation. British J Ophthalmol. 2020;104:678.

    Article  Google Scholar 

  14. Aisenbrey S, Gelisken F. Surgical treatment of peripapillary choroidal neovascularisation. Br J Ophthalmol. 2007;91:1027–30.

  15. Bandello F, Lanzetta P, Battaglia Parodi M, Roman-Pognuz D, Saviano S, Ravalico G. Photodynamic therapy of subfoveal recurrences after laser photocoagulation of extrafoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2003;241:567–70.

    Article  PubMed  Google Scholar 

  16. Newman DK. Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye (Lond). 2016;30:202–10.

    Article  PubMed  Google Scholar 

  17. Busbee BG, Brown MM, Brown GC, Sharma S. CME review: A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina. 2003;23:279–87.

    Article  PubMed  Google Scholar 

  18. Hoeh AE, Schaal KB, Ach T, Dithmar S. Treatment of Peripapillary Choroidal Neovascularization with Intravitreal Bevacizumab. European J Ophthalmol. 2009;19:163–5.

    Article  Google Scholar 

  19. Mansour AM, Mackensen F, Arevalo JF, Ziemssen F, Mahendradas P, Mehio-Sibai A, et al. Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization. American J Ophthalmol. 2008;146:410–6.e1.

    Article  Google Scholar 

  20. Ozgonul C, Moinuddin O, Munie M, Lee MS, Bhatti MT, Landau K, et al. Management of Peripapillary Choroidal Neovascular Membrane in Patients With Idiopathic Intracranial Hypertension. J Neuro-Ophthalmol. 2019;39:451–7.

  21. Roy R, Saurabh K, Bansal A, Kumar A, Majumdar AK, Paul SS. Inflammatory choroidal neovascularization in Indian eyes: Etiology, clinical features, and outcomes to anti-vascular endothelial growth factor. Indian J Ophthalmol. 2017;65:295–300.

  22. Stanescu N, Friehmann A, Nemet A, Keshet Y, Ohayon A, Greenbaum E, et al. Long-term outcomes of anti-vascular endothelial growth factor treatment in peripapillary choroidal neovascularisation due to age-related macular degeneration. Eye. 2023;37:1202–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada

    Angelica Hanna

  2. Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada

    Aswen Sriranganathan

  3. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada

    Peter Kertes, Gary Yau & Rahul Sharma

  4. John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Peter Kertes, Gary Yau & Rahul Sharma

Authors
  1. Angelica Hanna
    View author publications

    Search author on:PubMed Google Scholar

  2. Aswen Sriranganathan
    View author publications

    Search author on:PubMed Google Scholar

  3. Peter Kertes
    View author publications

    Search author on:PubMed Google Scholar

  4. Gary Yau
    View author publications

    Search author on:PubMed Google Scholar

  5. Rahul Sharma
    View author publications

    Search author on:PubMed Google Scholar

Contributions

RS, GY, and AH conceived the study concept and design. AH and AS collected the data. AH performed the data analysis and drafted the initial manuscript. RS, GY, and PK critically reviewed and revised the manuscript. RS, GY, and PK provided overall supervision of the project.

Corresponding author

Correspondence to Rahul Sharma.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hanna, A., Sriranganathan, A., Kertes, P. et al. Anti-vascular endothelial growth factor for the management of peripapillary choroidal neovascular membrane. Eye (2025). https://doi.org/10.1038/s41433-025-04080-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41433-025-04080-x

Search

Advanced search

Quick links

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载